![GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors | Journal for ImmunoTherapy of Cancer GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/8/e003005/F1.large.jpg)
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors | Journal for ImmunoTherapy of Cancer
![Frontiers | The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology Frontiers | The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology](https://www.frontiersin.org/files/Articles/662164/fimmu-12-662164-HTML/image_m/fimmu-12-662164-g001.jpg)
Frontiers | The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology
![Frontiers | Nrf2 Is a Central Regulator of Metabolic Reprogramming of Myeloid-Derived Suppressor Cells in Steady State and Sepsis Frontiers | Nrf2 Is a Central Regulator of Metabolic Reprogramming of Myeloid-Derived Suppressor Cells in Steady State and Sepsis](https://www.frontiersin.org/files/MyHome%20Article%20Library/370494/370494_Thumb_400.jpg)
Frontiers | Nrf2 Is a Central Regulator of Metabolic Reprogramming of Myeloid-Derived Suppressor Cells in Steady State and Sepsis
![JCI - Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS JCI - Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS](https://dm5migu4zj3pb.cloudfront.net/manuscripts/62000/62636/medium/JCI62636.f1.jpg)
JCI - Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS
![GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors | Journal for ImmunoTherapy of Cancer GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/8/e003005/F2.large.jpg)
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors | Journal for ImmunoTherapy of Cancer
![Frontiers | CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors Frontiers | CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors](https://www.frontiersin.org/files/Articles/506171/fimmu-11-00032-HTML/image_m/fimmu-11-00032-g001.jpg)
Frontiers | CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors
![ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia - ScienceDirect ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1097276521003658-fx1.jpg)
ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia - ScienceDirect
![Frontiers | Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer Frontiers | Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer](https://www.frontiersin.org/files/Articles/521445/fonc-10-00748-HTML/image_m/fonc-10-00748-g003.jpg)
Frontiers | Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer
![Frontiers | Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer Frontiers | Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer](https://www.frontiersin.org/files/MyHome%20Article%20Library/521445/521445_Thumb_400.jpg)
Frontiers | Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer
![Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy | Nature Communications Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-35130-7/MediaObjects/41467_2022_35130_Fig1_HTML.png)